JP2019502384A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502384A5 JP2019502384A5 JP2018535034A JP2018535034A JP2019502384A5 JP 2019502384 A5 JP2019502384 A5 JP 2019502384A5 JP 2018535034 A JP2018535034 A JP 2018535034A JP 2018535034 A JP2018535034 A JP 2018535034A JP 2019502384 A5 JP2019502384 A5 JP 2019502384A5
- Authority
- JP
- Japan
- Prior art keywords
- configuration
- ctcs
- nuclear
- ctc
- genomic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021054561A JP2021118689A (ja) | 2016-01-06 | 2021-03-29 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
| JP2023086666A JP2023116530A (ja) | 2016-01-06 | 2023-05-26 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275659P | 2016-01-06 | 2016-01-06 | |
| US62/275,659 | 2016-01-06 | ||
| US201662344703P | 2016-06-02 | 2016-06-02 | |
| US62/344,703 | 2016-06-02 | ||
| PCT/US2017/012317 WO2017120324A1 (en) | 2016-01-06 | 2017-01-05 | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021054561A Division JP2021118689A (ja) | 2016-01-06 | 2021-03-29 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019502384A JP2019502384A (ja) | 2019-01-31 |
| JP2019502384A5 true JP2019502384A5 (https=) | 2020-02-06 |
Family
ID=59273946
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535034A Pending JP2019502384A (ja) | 2016-01-06 | 2017-01-05 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
| JP2021054561A Pending JP2021118689A (ja) | 2016-01-06 | 2021-03-29 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
| JP2023086666A Pending JP2023116530A (ja) | 2016-01-06 | 2023-05-26 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021054561A Pending JP2021118689A (ja) | 2016-01-06 | 2021-03-29 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
| JP2023086666A Pending JP2023116530A (ja) | 2016-01-06 | 2023-05-26 | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190025312A1 (https=) |
| EP (1) | EP3400311A4 (https=) |
| JP (3) | JP2019502384A (https=) |
| CN (2) | CN115323054A (https=) |
| AU (2) | AU2017205443A1 (https=) |
| CA (1) | CA3010311A1 (https=) |
| EA (1) | EA201891571A1 (https=) |
| WO (1) | WO2017120324A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011050103A1 (en) | 2009-10-21 | 2011-04-28 | The Scripps Research Institute | Method of using non-rare cells to detect rare cells |
| US10527624B2 (en) | 2014-01-27 | 2020-01-07 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| EP3108246B1 (en) | 2014-02-21 | 2019-10-09 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| US11514289B1 (en) | 2016-03-09 | 2022-11-29 | Freenome Holdings, Inc. | Generating machine learning models using genetic data |
| US11222194B2 (en) * | 2016-12-30 | 2022-01-11 | Ventana Medical Systems, Inc. | Automated system and method for creating and executing a scoring guide to assist in the analysis of tissue specimen |
| EP3431611A1 (en) | 2017-07-21 | 2019-01-23 | Menarini Silicon Biosystems S.p.A. | Improved method and kit for the generation of dna libraries for massively parallel sequencing |
| US11348661B2 (en) | 2018-05-14 | 2022-05-31 | Tempus Labs, Inc. | Predicting total nucleic acid yield and dissection boundaries for histology slides |
| US10957041B2 (en) | 2018-05-14 | 2021-03-23 | Tempus Labs, Inc. | Determining biomarkers from histopathology slide images |
| CN109060989B (zh) * | 2018-08-29 | 2021-07-30 | 重庆市肿瘤研究所 | 应用iTRAQ技术研究三阴性乳腺癌外泌体差异表达蛋白的方法 |
| CN109658981B (zh) * | 2018-12-10 | 2022-10-04 | 海南大学 | 一种单细胞测序的数据分类方法 |
| ES3047360T3 (en) * | 2019-03-26 | 2025-12-03 | Tempus Ai Inc | Determining biomarkers from histopathology slide images |
| KR102343947B1 (ko) * | 2019-09-30 | 2021-12-27 | 주식회사 피디젠 | 환자 정보 분석을 이용한 암 재발 및 전이 모니터링 시스템을 이용한 비즈니스모델 |
| EP3965119A1 (en) * | 2020-09-04 | 2022-03-09 | Koninklijke Philips N.V. | Methods for estimating heterogeneity of a tumour based on values for two or more genome mutation and/or gene expression related parameter, as well as corresponding devices |
| CN112164420B (zh) * | 2020-09-07 | 2021-07-20 | 厦门艾德生物医药科技股份有限公司 | 一种基因组瘢痕模型的建立方法 |
| JP2024522266A (ja) * | 2021-04-19 | 2024-06-12 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 病理スライド画像からの遺伝子改変予測のための方法及びシステム |
| EP4445141A1 (en) * | 2021-12-07 | 2024-10-16 | Epic Sciences, Inc. | Enhanced characterization of breast cancer |
| WO2023122427A1 (en) * | 2021-12-21 | 2023-06-29 | Foundation Medicine, Inc. | Methods and systems for predicting genomic profiling success |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2623405C (en) * | 2005-09-20 | 2014-11-25 | Immunivest Corporation | Methods and composition to generate unique sequence dna probes labeling of dna probes and the use of these probes |
| AU2014248007B2 (en) * | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| WO2015048740A1 (en) * | 2013-09-30 | 2015-04-02 | The Scripps Research Institute | Genotypic and phenotypic analysis of circulating tumor cells to monitor tumor evolution in prostate cancer patients |
| CA2937051A1 (en) * | 2014-01-17 | 2015-07-23 | Ontario Institute For Cancer Research (Oicr) | Biopsy-driven genomic signature for prostate cancer prognosis |
| US20160011198A1 (en) * | 2014-01-27 | 2016-01-14 | Epic Sciences, Inc. | Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc) |
| US10527624B2 (en) * | 2014-01-27 | 2020-01-07 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| US20150212089A1 (en) * | 2014-01-30 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
-
2017
- 2017-01-05 US US16/068,348 patent/US20190025312A1/en not_active Abandoned
- 2017-01-05 EA EA201891571A patent/EA201891571A1/ru unknown
- 2017-01-05 CA CA3010311A patent/CA3010311A1/en active Pending
- 2017-01-05 AU AU2017205443A patent/AU2017205443A1/en not_active Abandoned
- 2017-01-05 WO PCT/US2017/012317 patent/WO2017120324A1/en not_active Ceased
- 2017-01-05 EP EP17736324.9A patent/EP3400311A4/en active Pending
- 2017-01-05 JP JP2018535034A patent/JP2019502384A/ja active Pending
- 2017-01-05 CN CN202210926315.3A patent/CN115323054A/zh active Pending
- 2017-01-05 CN CN201780015212.9A patent/CN108884494A/zh active Pending
-
2021
- 2021-03-29 JP JP2021054561A patent/JP2021118689A/ja active Pending
-
2022
- 2022-01-19 US US17/579,437 patent/US20220390451A1/en not_active Abandoned
-
2023
- 2023-04-13 AU AU2023202282A patent/AU2023202282A1/en not_active Abandoned
- 2023-05-26 JP JP2023086666A patent/JP2023116530A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019502384A5 (https=) | ||
| Magen et al. | Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma | |
| Ding et al. | Patient-derived micro-organospheres enable clinical precision oncology | |
| Garris et al. | Dendritic cells, the T-cell-inflamed tumor microenvironment, and immunotherapy treatment response | |
| JP2018534595A5 (https=) | ||
| de Chaisemartin et al. | Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer | |
| Tsujikawa et al. | Quantitative multiplex immunohistochemistry reveals myeloid-inflamed tumor-immune complexity associated with poor prognosis | |
| Pruneri et al. | Tumor infiltrating lymphocytes in early breast cancer | |
| Grisham et al. | BRAF mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer | |
| Desitter et al. | A new device for rapid isolation by size and characterization of rare circulating tumor cells | |
| Stankiewicz et al. | Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas | |
| Dervovic et al. | In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer | |
| John et al. | Characterization of lymphomas developing in immunodeficient mice implanted with primary human non–small cell lung cancer | |
| Akamatsu et al. | The impact of clinical outcomes according to EGFR mutation status in patients with locally advanced lung adenocarcinoma who recieved concurrent chemoradiotherapy | |
| JP2013539857A5 (https=) | ||
| Liu et al. | Characterization of primary ovarian cancer cells in different culture systems | |
| Shields et al. | Late-stage MC38 tumours recapitulate features of human colorectal cancer–implications for appropriate timepoint selection in preclinical studies | |
| JP2020522697A5 (https=) | ||
| Bruschini et al. | CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions | |
| JP2018532422A (ja) | 疾患の組織学的診断および処置方法 | |
| JP2023516954A (ja) | 遺伝子サンプリングにおける統計的バイアスの軽減 | |
| Awe et al. | Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups | |
| Ross et al. | The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancer | |
| Premasekharan et al. | An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer | |
| Yao et al. | Tumor cells are dislodged into the pulmonary vein during lobectomy |